Imclone Systems, Inc.

Antyra Inc.

Other

Novo Nordisk A/s

Corixa Corporation

Neil I Goldstein

Patricia Rockwell

Arthur J Blume

Renee Brissette

Renuka Pillutla

Olga Dedova

Paul B Fisher

Jose William Saldanha

Steven Tarran Jones

Per Hertz Hansen

Charles T Tackney

Ku-chuan Hsiao

Hao Liu

John Prendergast

Lauge Schäffer

Jakob Brandt

Jane Spetzler

Pinger Wang

Søren Østergaard

Michael Lennick

Yilong Sun

Paul Fletcher

Nicholas A Giorgio

Michael Spruyt

Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.

Insulin and IGF-1 receptor agonists and antagonists

A nucleic acid is provided which encodes a humanized antibody or fragment thereof, which encodes a protein which binds to human EGF-receptor. Monoclonal antibody 225 is the complementary determining region (CDR) donor.

Humanized anti-EGF receptor monoclonal antibody

The invention relates to a modified phage display method for detecting and identifying target and target binders. The modified methods involve transforming host cells with two separate phages of a target or target library and a target-binder library, and selecting to eliminate the non-paired targets and binders. The invention also relates to antibodies that bind to complexes of target and target binders; nucleic acids encoding target and target binders peptides; and the use of sequence information inherent in the targets and target binders for target validation using in silico approaches. The invention further relates to diagnostics and therapeutics employing the disclosed target and target binder peptides or polynucletides and their use in small molecule drug discovery; diagnostic and therapeutic applications directed to cancers and similar disorders; and site directed assays for high throughput drug screening.

Target specific screening and its use for identifying target binders

Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.

The invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation. In addition, the invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and a chemotherapeutic agent.

Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy

Chimeric and humanized monoclonal antibodies that specifically bind to an extracellular domain of a VEGF receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.

Chimeric and humanized monoclonal antibodies specific to VEGF receptors

Methods are provided for identifying agents that modulate the expression of genes, such as genes encoding tumor suppressor or tumor-promoting proteins. The methods generally comprise screening candidate agents for the ability to enhance expression of a tumor suppressor gene, such as mda-7, or for the ability to inhibit expression of a tumor-promoting gene within a cell. Modulating agents may be used, for example, within anti-cancer therapies.

Methods for indentifying anti-cancer agents

Monoclonal antibodies that specifically bind to an extracellular domain of a flt-1 receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.

Monoclonal antibodies specific to VEGF receptors and uses thereof

Monoclonal antibodies that specifically bind to an extracellular domain of a VEGF receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.

Single chain antibodies specific to VEGF receptors

Nucleic acid molecules comprising a nucleic acid sequence that encodes an amino acid sequence wherein the amino acid sequence consists of the variable region or of the hypervariable region of a monoclonal antibody that specifically binds to an extracellular domain of a VEGF receptor and neutralizes activation of the receptor.

Nucleic acid molecules encoding the variable or hypervariable region of

Methods of use of chimerized, humanized, and single chain antibodies

The present invention provides a polypeptide that is non-toxic in E. coli. The disclosed polypeptide comprises at least one antigenic sequence present in P.IA of N. gonorrhoeae and at least one antigenic sequence present in P.IB of N. gonorrhoeae. Further, the disclosed polypeptide of the invention is fused to a carrier peptide.

Growing community of inventors

Maplewood, NJ, United States of America

Neil I Goldstein